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OBJECTIVES: The Nplate® NEXUS (NEXUS) Program included a registry of patients
in theUnited States tomonitor the long-termsafety and assure safe use ofNplate®.
Adverse events of special interest include changes in bone marrow reticulin for-
mation and collagen fibrosis, worsened thrombocytopenia after cessation of
Nplate®, thrombotic/thromboembolic complications, new hematologic malignan-
cies and progression of malignancy in patients with pre-existing hematological
malignancies or myelodysplastic syndromes (MDS), and medication errors associ-
ated with serious outcomes. METHODS: Data were collected through structured
questionnaires completed by healthcare professionals registered for the NEXUS
Program at baseline and every 6 months thereafter. RESULTS: Between August 22,
2008 and January 31, 2011, 5,235 patients (51% female, mean age 62 years, median
baseline platelet count 20x109/L) had enrolled in the NEXUS Program and received
Nplate®. The reported diagnoses were ITP (88.3%), other (8.9%), thrombocytopenia
from hematologic or lymphatic malignancies (1.1%), MDS (1.0%), and thrombocy-
topenia from chemotherapy (0.6%). Before entry, 86.1% of patients had received ITP
therapies, most commonly corticosteroids (61.8%), IVIG (55.4%), and rituximab
(42.5%). At baseline, 62.9% of patients were receiving concurrent ITP therapy, in-
cluding corticosteroids (43.8%), IVIG (17.7%), and rituximab (11.4%). Prior to enroll-
ment, 24.7% of patients had a splenectomy. As of December 2011, the FDA and
Amgen concluded that the restricted elements of the REMS could be eliminated.
CONCLUSIONS: The majority of patients in the NEXUS Program receiving Nplate®
were reported to have an ITP diagnosis with a history of previous ITP therapies and
were receiving concurrent ITPmedications. Further information regarding the data
from the NEXUS Program and the evolution of the REMS programwill be discussed.
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OBJECTIVES: Little is known about the characteristics of duloxetine patients initi-
ating therapy for chronic lower back pain (CLBP). This study identified demo-
graphic and clinical characteristics associated with initiation of duloxetine versus
other painmedications among CLBP patients.METHODS: Adult CLBP patients who
initiated medication therapy (duloxetine, anticonvulsants, antidepressants, mus-
cle relaxants, non-steroidal anti-inflammatory drugs [NSAIDs], opioids, or benzo-
diazepines) between November 1, 2010-March 31, 2011 were selected frommedical
and pharmacy claims from Medco Health Solutions. Treatment initiation was de-
fined as no pill coverage of themedication over the previous 90 days. The dispense
date of the first initiated medication was set as the index date. Comorbidities and
prior medication use was assessed during the 6 months before the index date.
Multiple logistic regression models were performed to identify predictors of initi-
ating duloxetine versus other pain medication. Separate models were estimated
with Charlson comorbidity index (CCI)  use of selected medications, and individ-
ual comorbidities  number of unique medications, respectively. RESULTS: We
identified 38,943 CLBP patients (mean age 58.0 years; 62.8 % female) who initiated
opioids (36.0%), NSAIDs (21.1%), muscle relaxants (13.6%), benzodiazepines (8.9%),
antidepressants (8.7%), anticonvulsants (7.5%), or duloxetine (4.1%). Patients who
initiated duloxetine had significantly higher CCI and more inpatient stays than
patients who initiated other pain medications except for anticonvulsants. The
regression results showed older patientswere less likely to initiate duloxetine than
anticonvulsants or opioids. Patients with higher CCI weremore likely to initiate on
duloxetine except for anticonvulsants and antidepressants. Prior use of pregabalin,
gabapentin, antidepressants, and benzodiazepines were associated with a higher
likelihood of initiating duloxetine. Patients who had more unique medications,
peripheral vascular disease, or depression were more likely to initiate duloxetine.
CONCLUSIONS: Presence of selected demographic characteristics, comorbidities
and prior use of medications were significant predictors of duloxetine initiation
among CLBP patients.
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OBJECTIVES: The purpose of this study was to identify the demographic and clin-
ical characteristics associated with the initiating dose of duloxetine among pa-
tients with chronic lower back pain (CLBP). METHODS: Medical and pharmacy
claims of CLBP patients who initiated duloxetine were analyzed. Initiation was
defined as no duloxetine coverage in the 90 days preceding the first duloxetine
prescription fill betweenNovember 1, 2010-March 31, 2011, Comorbidities and prior
medication use were assessed during 6 months prior to initiation (the index date).
Multiple logistic regressionmodels were estimated to identify predictors of initiat-
ing 60mg or 60mg versus 60mg, the recommended dose. RESULTS: 1,583 CLBP
patients (mean age 57.3 years; 69.2% female) who initiated duloxetine were iden-
tified. Common comorbidities were hypertension (47.6%) depression (37.2%) and
diabetes (21.1%). Opioids (79.7%) were the most commonly used pain medications
prior to duloxetine initiation, followed by antidepressants (54.6%) and muscle re-
laxants (40.9%). Regression results suggested that, patients 75 years were more
likely to initiate on a dose 60mg (Odds Ratio [OR]: 2.23, 95% confidence interval
[CI]: 1.46-3.38) and less likely to initiate on a dose60mg (OR: 0.39, 95% CI: 0.17-0.90)
than those 18-44 years old. Patients who used duloxetine in 6 months prior were
less likely to start on 60mg (0.64, 95% CI: 0.41-1.00), and more likely to start on
60mg (OR: 2.09, 95% CI: 1.29-3.39). Patients with prior use of opioid (OR: 0.71, 95%
CI: 0.54-0.95) or depression (OR: 0.75, 95% CI: 0.59-0.96) were less likely to initiate on
60mg, whereas patients with rheumatologic disease were more likely to start on
60mg (OR: 2.48, 95% CI: 1.34-4.59). CONCLUSIONS: A majority of CLBP patients
initiated duloxetine at 60mg/day. Presence of selected comorbidities and prior use
of medications were associated with certain initiating doses of duloxetine among
CLBP patients.
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OBJECTIVES: To develop and validate an algorithm enabling the classification of
prophylactic (PPL) vs. on-demand (OD) factor VIII (FVIII) regimens for hemophilia A
(HA) patients in health insurance claims databases, thereby enabling the assess-
ment of these treatment approaches in real-world settings. METHODS: Prescrip-
tion records from two 2010-2011 US specialty pharmacy dispensing databaseswere
used. Males aged 2 years old with a HA diagnosis, 1 prescription for FVIII, no
anti-inhibitor agents ormixed PPL/OD FVIII regimenswere included. Four variables
common to specialty pharmacy and standard claims databases were used to de-
velop the algorithm: age at first observed dispensing (a weight proxy); total units of
FVIII dispensed (TUFVIII); and if TUFVIII data were not available, vial potency (IU/
vial) and number of vials dispensed were used to calculate TUFVIII dispensed (IU/
vial*number of vials dispensed). Different TUFVIII thresholds per age groups 2-12,
13-16, 17-27, and 28 formed the algorithm. Several TUFVIII thresholds for each
age group were iteratively tested over various observation lengths for patients
classified as on PPL (vs. OD) regimen. Each algorithm was assessed against actual
regimens prescribed based on physician notes using sensitivity, specificity, posi-
tive and negative predictive values (PPV & NPV). RESULTS: 445 patients were iden-
tified with 65% on PPL regimens. Patients receiving OD regimens were significantly
older than those receiving PPL regimens (Mean age [years] OD: 24.417.1; PPL:
19.613.0; p0.02). The best-performing algorithm was based on TUFVIII thresh-
olds of 43,920 (age group 2-12), 104,100 (13-16), 139,200 (17-27), and 176,970 (28),
over the first 12months of observation. Sensitivity, specificity, PPV, andNPV of this
algorithm were 0.81, 0.82, 0.89, and 0.71, respectively. CONCLUSIONS: The best-
performing algorithm showed promising performance validity with PPV0.89 for
ascertainment of PPL FVIII regimens in HA patients. Further refinement of the
classification algorithm on larger populations is needed.
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OBJECTIVES:Todescribe the available approaches for enhancing interpretability of
meta-analyses involving HRQL outcomes. METHODS: Narrative review of the
methodological literature. Application to two illustrative examples-one investigat-
ing the effect of interventions for respiratory rehabilitation in chronic obstructive
pulmonary disease (COPD), and one comparing pain in patients undergoing lapa-
roscopic cholecystectomy receiving dexamethasone or placebo. RESULTS: We
identified 12 approaches in 3 categories: 1) Summary estimates derived from the
pooled SMD: conversion to units of the most familiar instrument, or conversion to
risk difference or odds ratio. These approaches remain vulnerable to differential
variability in populations; 2) Summary estimates derived from the individual trial
summary statistics: conversion to units of the most familiar instrument or to ratio
of means. Both are appropriate complementary approaches to measures derived
from converted probabilities; and 3) Summary estimates derived from the individ-
ual trial summary statistics and established minimally important differences
(MIDs) for all instruments: presentation in MID units or conversion to risk differ-
ence or odds ratio. Risk differences are ideal for balancing desirable and undesir-
able consequences of alternative interventions. CONCLUSIONS: Use of these ap-
proaches may enhance the interpretability and the usefulness of systematic
reviews involving HRQL outcomes.
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OBJECTIVES: To evaluate the Medicaid Analytic Extract (MAX) database for use in
pharmacoepidemiologic research using hemophilia as a test case.METHODS: This
research was conducted using MAX data (years 2000-2004) for 49 states (excluding
AZ) and DC. We identified patients who received recombinant factor VIIa (rFVIIa),
factor VIII inhibitor bypass activity (FEIBA), factor VIII or factor IX or had a diagnosis
code for coagulation defects (ICD-9 286.xx). Use of antihemophilic drugs was iden-
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tified through either pharmacy dispensing or provider administration codes. Sev-
eral definitions were applied to identify patients with hemophilia A and B. Health
care utilization and costs for each year were characterized for rFVIIa/FEIBA users.
RESULTS: After excluding 5 states with extensive use of managed care (for which
claimsmay be incomplete), a source population of approximately 63million people
was identified. A total of 130,946 patientsmet the inclusion criteria, of which 10,693
had at least one diagnosis for hemophilia A and 2,032 for hemophilia B. Fewer than
10% were enrolled in managed care in any year. Restricting to males reduced the
sample size to 7292 for hemophilia A (mean age 15.4 years) and 1557 for hemophilia
B (mean age 13.8 years), and these numbers correspond to the expected relative
frequencies of these disorders (4:1). Users of rFVIIa or FEIBAwere approximately 5%
of the cohort and these patients were characterized by extensive use of health care
with on average, a physician visit every 6 weeks and yearly total costs approaching
$1,000,000. CONCLUSIONS: As with any administrative data source, researchers
should be aware of limitations within MAX data, such as the validity of diagnostic
codes and the potential incompleteness of data for certain population subgroups.
Broad demographic coverage, however, large size, and extensive representation of
children make MAX useful, particularly for studying low-prevalence conditions
such as hemophilia.
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OBJECTIVES: The Pain Impact Questionnaire Revised (PIQ-R) is a 6-item patient-
reported measure developed with Item Response Theory and normed against a
general US population sample (GPS). The PIQ-R yields the Pain Impact Score (PIS),
and has been shown to have strong psychometric properties. The traditional stan-
dard PIQ-R uses a 4-week recall; this analysis tested the PIQ-R with a 1-week recall
period. The shorter recall is useful for monitoring interventions with a relatively
rapid impact on pain. METHODS: Identical psychometric tests were run on the
1-week and 4-week PIQ-R using a representative GPS. Internal consistency was
measured with Chronbach’s alpha. Construct validity was tested first by correlat-
ing PIS with a self-reported 0-100 general health rating scale, then by calculating
mean PIS by reported impact of pain condition and other conditions. Discriminant
validity was demonstrated by correlating PIS with the Physical (PCS) and Mental
(MCS) Component Summaries of the SF-12v2 Health Survey. Finally, the unidimen-
sionality of the PIS was explored through factor analysis. RESULTS: Chronbach’s
alpha was .95 for 4-week recall and .96 for 1-week. Correlations between PIS and
general health ratings were strong, at .60 for 4-week recall and .61 for 1-week. The
mean PIS among people with back pain rose monotonically with the reported im-
pact of the condition, for both 1-week and 4-week recall. Conversely, there was no
such rise in PIS by impact of seasonal allergies, which do not generally cause pain.
Among people reporting nomedical conditions,mean PIS in both versionswaswell
below the GPS mean. Both versions of the PIS correlated more strongly with PCS
than with MCS, and exhibited a highly unidimensional structure. CONCLUSIONS:
In all psychometric tests, the 1-week version of the PIQ-R showed nearly identical
results to the 4-week version. Both versions show robust internal consistency,
construct validity, discriminant validity and unidimensionality.
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OBJECTIVES: Little is known about the relative importance to patients and their
willingness to accept tradeoffs among immunoglobulin (IG) treatment administra-
tion attributes. The objective of this study was to quantify patient and parent
preferences for administration attributes of IG treatments. METHODS: United
States adult patients and parents of children with a self-reported physician diag-
nosis of a primary immunodeficiency disorder completed a web-enabled, choice-
format conjoint survey that presented a series of 12 choice questions, each includ-
ing a pair of hypothetical IG-treatment profiles. Each profile was defined by mode,
frequency, location, number of needle sticks, and duration. Before answering the
choice questions, respondents were told to assume all treatments worked equally
well. Choice questionswere based on aD-efficient experimental design. Preference
weights for attribute levelswere estimated using random-parameters logit for each
group. All respondents provided online informed consent. RESULTS: A total of 252
patients and 66 parents completed the choice questions appropriately. Both groups
prefered monthly to weekly, home setting, shorter duration and fewer needle
sticks of IG treatment relative to alternative choices (P  0.05). Mode of adminis-
trationwas the least important attribute to both groups; however, parents strongly
preferred self-administration to an appointment with a health care professional (P
 0.05) whereas patients slightly preferred self-administration butwere indifferent
to the two modes. Overall, 98% of parents and 84% of patients preferred therapy
with options of monthly frequency, home setting, shorter duration, and fewer
needle sticks. CONCLUSIONS: IG treatments that provide the option of a monthly
frequency, home setting, shorter duration, and fewer needle sticks may address
the needs of both patients and parents.
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CARDIOVASCULAR DISORDERS – Clinical Outcomes Studies
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AND THE RISK OF CARDIAC INJURY IN BREAST CANCER
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OBJECTIVES: To estimate the risk of cardiac injury associated with modern radia-
tion in a population of women with different cardiovascular (CV) risk. METHODS:
The data used for this analysis are from the linked SEER-Medicare database. The
study included women aged 66 years and older with stage 0 - III breast cancer
diagnosed between 2000 and 2005. Women were retrospectively categorized into
low, intermediate, or high risk groups based on the presence of certain clinical
diagnosis. The risk for a hospitalization for a cardiac event was estimated using a
multivariable Cox model. RESULTS: The median follow-up time was 40 months.
Among the 91,612 women with AJCC stage 0 - III breast cancer: 39,555 (43.2%) were
treated with radiation therapy and 52,057 (56.8%) were not. Radiation-treated
women were younger, were likely to have pre-existing CV disease, CV risk factors
and more advanced stage at diagnosis (P  0.001). The following baseline charac-
teristics were significant predictors of an increased risk of hospitalization for a
cardiac event: decreasing year of diagnosis (HRs 1.08– 1.19; 95%CI, 1.02– 1.25), age
at diagnosis (HRs 1.59– 2.50; 95%CI, 2.50– 2.61), AJCC stage I – III (HRs 1.13– 1.29;
95% CI, 1.08– 1.38), the number of comorbid conditions (HRs  1.74– 4.35; 95% CI,
1.68– 4.59), and left-sided tumor (HR  1.03; 95% CI, 1.00– 1.06). Chemotherapy did
confer an elevated risk (HR  1.16; 95% CI, 1.12-1.20) for a hospitalized CV event.
The use of radiotherapy in women categorized as high risk for a future CV
event had an increased risk (HR 1.34; 95% CI, 1.29– 1.39) for a hospitalized CV
event compared to thosewith an intermediate risk or low risk.CONCLUSIONS: The
adverse effects of radiation in high risk patients may require the use of techniques
that minimize the heart from radiation exposure.
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FIBRILLATION
Laliberté F1, Dea K1, Lamori JC2, Mody SH2, Jones JL2, Arledge MD2, Damaraju CV2,
Duh MS3, Schein JR2, Lefebvre P1
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Janssen Scientific Affairs, LLC, Titusville, NJ,
USA, 3Analysis Group, Inc., Boston, MA, USA
OBJECTIVES:There are limited data suggesting that gastrointestinal (GI) conditions
are common in patients with atrial fibrillation (AF). Many agents utilized by pa-
tients with AF, however, are known to increase the risk of GI events. The study
objective was to describe the risk of GI events among patients with AF.METHODS:
Insurance health care claims between January 2005 and December 2009 from the
Thomson Reuters MarketScan® database were analyzed. Subjects aged 18 years
with 180 days of continuous insurance coverage prior to the index AF diagnosis
were selected. GI events were identified from claims with a primary or secondary
diagnosis code for any GI condition. The subset of GI conditions consistent with
dyspepsia was also reported. The risk of GI events was assessed using cumulative
incidence (new GI events/patients without GI condition at baseline) and incidence
rates (IRs; number of patients with an event/patient-years of observation).
RESULTS:A total of 557,123 AF patients were identified, of whom 143,955 (26%) had
a history of a GI condition at baseline. Themean AF patient age was 68.2 years; 45%
were female. Over the 180-day baseline and mean follow-up of 543 days, 308,823
(55.4%) patients had at least one GI event. Dyspepsia was the most common GI
event seen in 29.6% of patients. The cumulative incidences of any GI event and
dyspepsia were 40% and 19%, respectively. The corresponding IRs were 38.8 and
14.7 events per 100 patient–years, respectively. Additionally, during the baseline
period, 359,398 patients (65%) had at least one medication dispensed that had the
potential to cause GI tolerability issues. CONCLUSIONS: In this large claims data-
base, AF was associated with a 40% risk of developing a GI event, predominantly
dyspepsia. Higher propensity for GI events and agents that selectively cause higher
symptomatic GI rates may relate to poor medication adherence in AF patients.
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EVALUATION OF VTE PROPHYLAXIS, SURGICAL SITE BLEEDING, AND
SURGICAL-SITE INFECTIONS FOLLOWING ORTHOPAEDIC ARTHROPLASTY: A
NESTED CASE–CONTROL MEDICAL CHART REVIEW STUDY
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OBJECTIVES: Post-operative surgical-site infections (SSI) are a leading cause of
prosthetic complications, which include revision surgery. There are insufficient
data to either confirm or refute the hypothesis that post-operative surgical-site
bleeding (SSB) is a mediating pathophysiologic factor linking pharmacologic VTE
prophylaxis to an increased risk of SSI. METHODS: This study addresses this evi-
dence gap by examining the rates and associated risk factors for SSI and yields an
answer on the potential causal relationship between post-discharge thrombopro-
phylaxis, SSB, and subsequent SSI. A cohort of patients with total hip or knee
arthroplasties (from 2005 to 2008) was identified from HealthCore Integrated Re-
searchDatabase (HIRDSM). A random sample of eligible claims recordswas selected
and augmented with the data abstracted from linked hospital medical charts to
conduct a case–control analysis. RESULTS: The study cohort comprised 33,826
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